REFERENCES
1. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
2. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
3. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006;58:782-97.
4. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995;9:1608-21.
5. Pearson OH, Eliel LP. Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. J Am Med Assoc 1950;144:1349-53.
7. Tissing WJ, Meijerink JP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003;17:17-25.
8. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol 2017;35:975-83.
9. Arico M, Basso G, Mandelli F, Rizzari C, Colella R, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 1995;75:1684-93.
10. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94:1209-17.
11. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92:2730-41.
12. Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S. New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol 2018; doi: 10.1200/JCO.2017.77.3648.
13. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 2017;7:e577.
14. Smolej L. The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2012;21:1009-17.
15. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995;93:73-9.
16. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-7.
17. Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475-6.
18. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53.
19. Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, et al. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1055-65.
20. Yao QM, Li PP, Liang SM, Lu K, Zhu XJ, et al. Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression. Int J Clin Exp Pathol 2015;8:7921-8.
21. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010;116:2975-83.
22. Cirillo M, Reinke S, Klapper W, Borchmann S. The translational science of hodgkin lymphoma. Br J Haematol 2019;184:30-44.
23. Allen PB, Winter JN. Controversies in the approach to initial therapy of hodgkin lymphoma. Curr Oncol Rep 2019;21:39.
24. Eichenauer DA, Andre M, Johnson P, Fossa A, Casasnovas O, et al. Controversies in the treatment of classical hodgkin lymphoma. Hemasphere 2018;2:e149.
25. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet 2017;390:298-310.
26. Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858-67.
27. Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol 2018;5:e609-17.
28. Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 2019; doi: 10.1200/JCO.18.00605.
29. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
30. Blommestein HM, van Beurden-Tan CHY, Franken MG, Uyl-de Groot CA, Sonneveld P, et al. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A Network Meta-analysis. Haematologica 2019; doi: 10.3324/haematol.2018.206912.
31. Sekine L, Ziegelmann PK, Manica D, da Fonte Pithan C, Sosnoski M, et al. Frontline treatment for transplant-eligible multiple myeloma: a 6474 patients network meta-analysis. Hematol Oncol 2019;37:62-74.
32. Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis 2003;8:337-43.
33. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
34. Wright AP, Zilliacus J, McEwan IJ, Dahlman-Wright K, Almlof T, et al. Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 1993;47:11-9.
35. So AY, Cooper SB, Feldman BJ, Manuchehri M, Yamamoto KR. Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc Natl Acad Sci U S A 2008;105:5745-9.
36. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, et al. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009;324:407-10.
37. Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 2007;275:2-12.
39. Ricketson D, Hostick U, Fang L, Yamamoto KR, Darimont BD. A conformational switch in the ligand-binding domain regulates the dependence of the glucocorticoid receptor on Hsp90. J Mol Biol 2007;368:729-41.
40. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011;145:224-41.
41. Morrison N, Eisman J. Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 1993;8:969-75.
42. Lim HW, Uhlenhaut NH, Rauch A, Weiner J, Hubner S, et al. Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res 2015;25:836-44.
43. Hudson WH, Youn C, Ortlund EA. The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol 2013;20:53-8.
44. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal 2010;3:ra8.
45. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990;62:1205-15.
46. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990;62:1189-204.
47. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990;62:1217-26.
48. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994;91:752-6.
49. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14:2314-29.
51. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996;383:726-8.
52. Zhang Z, Jones S, Hagood JS, Fuentes NL, Fuller GM. STAT3 acts as a co-activator of glucocorticoid receptor signaling. J Biol Chem 1997;272:30607-10.
53. Takeda T, Kurachi H, Yamamoto T, Nishio Y, Nakatsuji Y, et al. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J Endocrinol 1998;159:323-30.
54. Robertson S, Rohwer JM, Hapgood JP, Louw A. Impact of glucocorticoid receptor density on ligand-independent dimerization, cooperative ligand-binding and basal priming of transactivation: a cell culture model. PLoS One 2013;8:e64831.
55. Hapgood JP, Avenant C, Moliki JM. Glucocorticoid-independent modulation of GR activity: implications for immunotherapy. Pharmacol Ther 2016;165:93-113.
56. Vernocchi S, Battello N, Schmitz S, Revets D, Billing AM, et al. Membrane glucocorticoid receptor activation induces proteomic changes aligning with classical glucocorticoid effects. Mol Cell Proteomics 2013;12:1764-79.
57. Gutierrez-Mecinas M, Trollope AF, Collins A, Morfett H, Hesketh SA, et al. Long-lasting behavioral responses to stress involve a direct interaction of glucocorticoid receptors with ERK1/2-MSK1-Elk-1 signaling. Proc Natl Acad Sci U S A 2011;108:13806-11.
58. Samarasinghe RA, Witchell SF, DeFranco DB. Cooperativity and complementarity: synergies in non-classical and classical glucocorticoid signaling. Cell Cycle 2012;11:2819-27.
59. Sionov RV, Cohen O, Kfir S, Zilberman Y, Yefenof E. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med 2006;203:189-201.
60. Talaber G, Boldizsar F, Bartis D, Palinkas L, Szabo M, et al. Mitochondrial translocation of the glucocorticoid receptor in double-positive thymocytes correlates with their sensitivity to glucocorticoid-induced apoptosis. Int Immunol 2009;21:1269-76.
61. Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011;286:3177-84.
62. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435-41.
63. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 1999;274:27857-66.
64. de Lange P, Koper JW, Brinkmann AO, de Jong FH, Lamberts SW. Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. Mol Cell Endocrinol 1999;153:163-8.
65. Hecht K, Carlstedt-Duke J, Stierna P, Gustafsson J, Bronnegard M, et al. Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. J Biol Chem 1997;272:26659-64.
66. Brogan IJ, Murray IA, Cerillo G, Needham M, White A, et al. Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: lack of effect of glucocorticoid receptor beta. Mol Cell Endocrinol 1999;157:95-104.
67. Kino T, Manoli I, Kelkar S, Wang Y, Su YA, et al. Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochem Biophys Res Commun 2009;381:671-5.
68. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006;1069:1-9.
69. Kino T, Su YA, Chrousos GP. Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci 2009;66:3435-48.
70. Shahidi H, Vottero A, Stratakis CA, Taymans SE, Karl M, et al. Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem Biophys Res Commun 1999;254:559-65.
71. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Kanemitsu S, et al. Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2005;45:121-7.
72. Rivers C, Levy A, Hancock J, Lightman S, Norman M. Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab 1999;84:4283-6.
73. Beger C, Gerdes K, Lauten M, Tissing WJ, Fernandez-Munoz I, et al. Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach. Br J Haematol 2003;122:245-52.
74. Bedewy AM, El-Maghraby SM, Kandil NS, El-Bendary WR. The prognostic value of glucocorticoid receptors for adult acute lymphoblastic leukemia. Blood Res 2015;50:235-41.
75. Lauten M, Fernandez-Munoz I, Gerdes K, von Neuhoff N, Welte K, et al. Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2009;52:459-63.
76. Moalli PA, Pillay S, Krett NL, Rosen ST. Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res 1993;53:3877-9.
77. de Lange P, Segeren CM, Koper JW, Wiemer E, Sonneveld P, et al. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res 2001;61:3937-41.
78. Huang M, Inukai T, Kagami K, Abe M, Shinohara T, et al. Splicing variant profiles and single nucleotide polymorphisms of the glucocorticoid receptor gene in relation to glucocorticoid sensitivity of B-cell precursor acute lymphoblastic leukaemia. Hematol Oncol 2018;36:245-51.
79. Silva CM, Powell-Oliver FE, Jewell CM, Sar M, Allgood VE, et al. Regulation of the human glucocorticoid receptor by long-term and chronic treatment with glucocorticoid. Steroids 1994;59:436-42.
80. Schmidt S, Irving JA, Minto L, Matheson E, Nicholson L, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J 2006;20:2600-2.
81. Gruber G, Carlet M, Turtscher E, Meister B, Irving JA, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia 2009;23:820-3.
82. Govindan MV, Pothier F, Leclerc S, Palaniswami R, Xie B. Human glucocorticoid receptor gene promotor-homologous down regulation. J Steroid Biochem Mol Biol 1991;40:317-23.
83. Ramamoorthy S, Cidlowski JA. Ligand-induced repression of the glucocorticoid receptor gene is mediated by an NCoR1 repression complex formed by long-range chromatin interactions with intragenic glucocorticoid response elements. Mol Cell Biol 2013;33:1711-22.
84. Burnstein KL, Jewell CM, Cidlowski JA. Human glucocorticoid receptor cDNA contains sequences sufficient for receptor down-regulation. J Biol Chem 1990;265:7284-91.
85. Sanchez-Vega B, Gandhi V. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). Br J Haematol 2009;144:856-64.
86. Hillmann AG, Ramdas J, Multanen K, Norman MR, Harmon JM. Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res 2000;60:2056-62.
87. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-64.
88. Oshima K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, Abate F, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2016;113:11306-11.
89. Grausenburger R, Bastelberger S, Eckert C, Kauer M, Stanulla M, et al. Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia. Leuk Lymphoma 2016;57:1163-73.
90. Liang YN, Tang YL, Ke ZY, Chen YQ, Luo XQ, et al. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. J Steroid Biochem Mol Biol 2017;172:62-8.
91. Tessel MA, Benham AL, Krett NL, Rosen ST, Gunaratne PH. Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer 2011;2:182-9.
92. Lv M, Zhang X, Jia H, Li D, Zhang B, et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways. Leukemia 2012;26:769-77.
93. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001;276:42714-21.
94. Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet 2015;47:607-14.
95. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005;18:331-42.
96. Yudt MR, Cidlowski JA. Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Mol Endocrinol 2001;15:1093-103.
97. Lu NZ, Collins JB, Grissom SF, Cidlowski JA. Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol Cell Biol 2007;27:7143-60.
98. Wu I, Shin SC, Cao Y, Bender IK, Jafari N, et al. Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes. Cell Death Dis 2013;4:e453.
100. Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 2018;25:65-80.
101. Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW. BH3-only proteins: Orchestrators of apoptosis. Biochim Biophys Acta 2011;1813:508-20.
102. Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 2017;31:37-42.
103. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 2003;278:23861-7.
104. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002;9:505-12.
105. Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, et al. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 2011;39:321-9. 9 e1-3
106. Zhao YN, Guo X, Ma ZG, Gu L, Ge J, et al. Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells. Med Oncol 2011;28:1609-17.
107. Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 2007;67:4482-90.
108. Lu J, Quearry B, Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006;580:3539-44.
109. Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005;105:2519-26.
110. Abrams MT, Robertson NM, Yoon K, Wickstrom E. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 2004;279:55809-17.
111. Melarangi T, Zhuang J, Lin K, Rockliffe N, Bosanquet AG, et al. Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. Cell Death Dis 2012;3:e372.
112. Iglesias-Serret D, de Frias M, Santidrian AF, Coll-Mulet L, Cosialls AM, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007;21:281-7.
113. Follin-Arbelet V, Misund K, Naderi EH, Ugland H, Sundan A, et al. The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. Sci Rep 2015;5:13001.
114. Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol 2015;6:230.
115. Kervoelen C, Menoret E, Gomez-Bougie P, Bataille R, Godon C, et al. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. Oncotarget 2015;6:26922-34.
116. Lopez-Royuela N, Balsas P, Galan-Malo P, Anel A, Marzo I, et al. Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells. Biochim Biophys Acta 2010;1803:311-22.
117. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003;162:613-22.
118. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000;10:1201-4.
119. Xie M, Yang A, Ma J, Wu M, Xu H, et al. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal. Cell Death Dis 2019;9:1013.
120. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010;116:3013-22.
121. Jing D, Bhadri VA, Beck D, Thoms JA, Yakob NA, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood 2015;125:273-83.
122. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.
123. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331-42.
124. Aries IM, Hansen BR, Koch T, van den Dungen R, Evans WE, et al. The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica 2013;98:1905-11.
125. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010;120:1310-23.
126. Lynch JT, Rajendran R, Xenaki G, Berrou I, Demonacos C, et al. The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. Mol Cancer 2010;9:38.
127. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, et al. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol 2014;164:352-65.
128. Aries IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 2018;215:3094-114.
129. Matassa DS, Amoroso MR, Maddalena F, Landriscina M, Esposito F. New insights into TRAP1 pathway. Am J Cancer Res 2012;2:235-48.
130. Aries IM, Jerchel IS, van den Dungen RE, van den Berk LC, Boer JM, et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. Leukemia 2014;28:1828-37.
131. Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev 2018;70:199-208.
132. Paakinaho V, Kaikkonen S, Makkonen H, Benes V, Palvimo JJ. SUMOylation regulates the chromatin occupancy and anti-proliferative gene programs of glucocorticoid receptor. Nucleic Acids Res 2014;42:1575-92.
133. Galliher-Beckley AJ, Cidlowski JA. Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 2009;61:979-86.
134. Kino T. GR-regulating Serine/Threonine kinases: new physiologic and pathologic implications. Trends Endocrinol Metab 2018;29:260-70.
135. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011;75:50-83.
136. Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, et al. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 2005;19:1569-83.
137. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, et al. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol 2002;16:2382-92.
138. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci U S A 1998;95:2050-5.
139. Galliher-Beckley AJ, Williams JG, Cidlowski JA. Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011;31:4663-75.
140. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood 2015;126:2202-12.
141. Takabe S, Mochizuki K, Goda T. De-phosphorylation of GR at Ser203 in nuclei associates with GR nuclear translocation and GLUT5 gene expression in Caco-2 cells. Arch Biochem Biophys 2008;475:1-6.
142. Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol 1997;17:3947-54.
143. Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, et al. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 2007;21:1552-68.
144. Blind RD, Garabedian MJ. Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes. J Steroid Biochem Mol Biol 2008;109:150-7.
145. Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, et al. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 2008;22:1754-66.
146. Miller AL, Garza AS, Johnson BH, Thompson EB. Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 2007;7:3.
147. Shi Y, Wang G, Muhowski EM, McCaw L, Wang C, et al. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. Leukemia 2019; doi: 10.1038/s41375-019-0381-4.
148. Polak R, Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2012;119:911-23.
149. Curran E, Smith SM. Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol 2014;26:469-75.
150. Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata JT, et al. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. J Cell Physiol 2018;233:1796-811.
151. Spijkers-Hagelstein JA, Pinhancos SS, Schneider P, Pieters R, Stam RW. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia 2014;28:761-9.
152. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer cell 2013;24:766-76.
153. Habib T, Sadoun A, Nader N, Suzuki S, Liu W, et al. AKT1 has dual actions on the glucocorticoid receptor by cooperating with 14-3-3. Molecular and cellular endocrinology 2017;439:431-43.
154. Lesovaya E, Agarwal S, Readhead B, Vinokour E, Baida G, et al. Rapamycin modulates glucocorticoid receptor function, blocks atrophogene REDD1, and protects skin from steroid atrophy. J Invest Dermatol 2018;138:1935-44.
155. Agarwal S, Mirzoeva S, Readhead B, Dudley JT, Budunova I. PI3K inhibitors protect against glucocorticoid-induced skin atrophy. EBioMedicine 2019;41:526-37.
156. Serafin V, Capuzzo G, Milani G, Minuzzo SA, Pinazza M, et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood 2017;130:2750-61.
157. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA. Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 2008;28:7309-22.
158. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60.
159. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol 2010;24:1136-50.
160. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 2017;31:2568-76.
161. Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, et al. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer 2009;100:1926-36.
162. Samuels AL, Heng JY, Beesley AH, Kees UR. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. Br J Haematol 2014;165:57-66.
163. Chan LN, Chen Z, Braas D, Lee JW, Xiao G, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 2017;542:479-83.
164. Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood 2017;129:3000-8.
165. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009;15:50-8.
166. Sionov RV, Kfir-Erenfeld S, Spokoini R, Yefenof E. A role for bcl-2 in notch1-dependent transcription in thymic lymphoma cells. Adv Hematol 2012;2012:435241.
167. Revollo JR, Oakley RH, Lu NZ, Kadmiel M, Gandhavadi M, et al. HES1 is a master regulator of glucocorticoid receptor-dependent gene expression. Sci Signal 2013;6:ra103.
168. Ratman D, Vanden Berghe W, Dejager L, Libert C, Tavernier J, et al. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol 2013;380:41-54.
169. Lonard DM, O’Malley B W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007;27:691-700.
170. King HA, Trotter KW, Archer TK. Chromatin remodeling during glucocorticoid receptor regulated transactivation. Biochim Biophys Acta 2012;1819:716-26.
171. Pottier N, Yang W, Assem M, Panetta JC, Pei D, et al. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008;100:1792-803.
172. Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 1999;18:5380-8.
173. Chen W, Rogatsky I, Garabedian MJ. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endocrinol 2006;20:560-72.
174. Rao NA, McCalman MT, Moulos P, Francoijs KJ, Chatziioannou A, et al. Coactivation of GR and NFKB alters the repertoire of their binding sites and target genes. Genome Res 2011;21:1404-16.
175. Oh KS, Patel H, Gottschalk RA, Lee WS, Baek S, et al. Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action. Immunity 2017;47:298-309.e5.
176. Uhlenhaut NH, Barish GD, Yu RT, Downes M, Karunasiri M, et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell 2013;49:158-71.
177. Reily MM, Pantoja C, Hu X, Chinenov Y, Rogatsky I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J 2006;25:108-17.
178. Bittencourt D, Wu DY, Jeong KW, Gerke DS, Herviou L, et al. G9a functions as a molecular scaffold for assembly of transcriptional coactivators on a subset of glucocorticoid receptor target genes. Proc Natl Acad Sci U S A 2012;109:19673-8.
179. Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 2016;30:1599-603.
180. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010;24:1258-64.
181. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470-80.
182. Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, et al. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Haematologica 2017;102:541-51.
183. van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, et al. BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood 2010;115:4810-9.
184. Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, et al. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem 2014;289:20502-15.
185. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004;116:511-26.
186. Perissi V, Scafoglio C, Zhang J, Ohgi KA, Rose DW, et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol Cell 2008;29:755-66.
187. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471:235-9.
188. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 2011;43:264-8.
189. Love MI, Huska MR, Jurk M, Schopflin R, Starick SR, et al. Role of the chromatin landscape and sequence in determining cell type-specific genomic glucocorticoid receptor binding and gene regulation. Nucleic Acids Res 2017;45:1805-19.
